Australia's most trusted
source of pharma news
Wednesday, 02 July 2025
Posted 2 July 2025 AM
New Zealanders will soon be able to access Wegovy, paying out of pocket for the weight loss drug.
Medsafe has approved Wegovy as as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of more than 30kg/m2, or those with between 27 and 30kg/m2 and at least one weight-related comorbidity. In adolescents older than 12, it's indicated for those with obesity and body weight above 60kg.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.